As of Jan 17
| -0.00085 / -0.14%|
The 1 analysts offering 12-month price forecasts for Arch Therapeutics Inc have a median target of 1.50, with a high estimate of 1.50 and a low estimate of 1.50. The median estimate represents a +145.84% increase from the last price of 0.61.
The current consensus among 1 polled investment analysts is to Outperform stock in Arch Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.